ONK’s CAR NK cells hit the TRAIL

ONK thinks its engineered TRAIL variants will make CAR NK cells more potent and resistance-proof against both hematological and solid cancers. 

The company, which spun out of National University of Ireland Galway in 2015, has applied its dual targeting allogeneic NK cell platform to four preclinical programs...